BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting


10/21/2013 9:58:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, Oct. 21, 2013 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 30, in San Diego, CA at the San Diego Convention Center.

"We're encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis," remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc. "Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we're on track for accomplishing that through our unique approach."

The posters will highlight Medac Pharma Inc.'s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.

Monday, October 28, 2013:

Title:

Successful Self-Administration of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen

Time:

Available: 9:00 a.m. PT 11:00 a.m. PT

Poster:

Abstract #1354

Location:

Exhibit Hall B2-C-D (8:30 a.m. PT 4:00 p.m. PT)



Title:

Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate

Time:

Available: 9:00 a.m. PT 11:00 a.m. PT

Poster:

Abstract # 1355

Location:

Exhibit Hall B2-C-D (8:30 a.m. PT 4:00 p.m. PT)

About Medac Pharma, Inc.

Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives. The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.

For more information, please visit www.medacpharma.com.

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Medac Pharma, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES